BEXIMCO PHARMA
BEXIMCO PHARMA is a Bangladeshi multinational pharmaceutical company producing and marketing branded generic medicines in Bangladesh and international markets.
Last updated August 24, 2026
AI crawler reads
2requests
1companies- Anthropic2
- Profile
- 2
- Controversies
- 0
- JSON · MD
- 0
- First read
- Nov 4, 2026
- Latest read
- Nov 4, 2026
From this site's server log
Overview
BEXIMCO PHARMA, formally Beximco Pharmaceuticals Limited, is a pharmaceutical company based in Bangladesh and a member of Bangladesh Export Import Company Limited, commonly known as BEXIMCO. The company was founded in 1976 and began operations in 1980. Its early manufacturing activity included products produced under licensing arrangements with Bayer AG of Germany and Upjohn of the United States. Over time, it developed into a producer and marketer of its own branded generic medicines. The company's portfolio serves a range of therapeutic areas, including infectious diseases, cancer, asthma, hypertension, and diabetes. Its business combines domestic supply in Bangladesh with exports to overseas markets. BEXIMCO PHARMA became the first pharmaceutical company from Bangladesh to sell medicines in the United States, an international regulatory and commercial milestone for the country's pharmaceutical sector. The company has also exported medicines to countries in Asia, including the Philippines, which became one of its ASEAN import markets in 2007. BEXIMCO PHARMA operates manufacturing facilities on a site of approximately 20 acres in Dhaka. The complex includes purpose-built production plants, an oral solid dosage facility, research laboratories, and warehouses. The company's production infrastructure was designed and installed with equipment and technical participation from partners in Germany, Switzerland, Sweden, Italy, the United Kingdom, and other countries. These facilities support the manufacture of a broad range of pharmaceutical dosage forms and the company's development of branded generic products. During the COVID-19 pandemic, BEXIMCO PHARMA gained international attention for its work on antiviral medicines. In May 2020, it introduced a generic version of remdesivir for COVID-19 treatment, describing it as the world's first generic remdesivir. The company later obtained production and marketing authorization for molnupiravir in Bangladesh, together with Eskayef Pharmaceuticals. Its branded generic version was marketed under the name Emorivir. These products represented an expansion from the company's established generic-drug business into high-profile pandemic treatments. The brand's principal positioning is that of a Bangladesh-based pharmaceutical manufacturer with international ambitions, combining local production capacity, branded generics, export activity, and participation in regulated global markets. Publicly available reference material identifies the company as active, but does not provide enough information here to establish a complete current executive roster, ownership breakdown, detailed revenue history, or a current official website URL.
History
BEXIMCO PHARMA is the pharmaceutical business formally known as Beximco Pharmaceuticals Limited. It is part of Bangladesh Export Import Company Limited, or BEXIMCO, and developed within Bangladesh's pharmaceutical manufacturing sector. The company was founded in 1976 and commenced operations in 1980. At the beginning of its operating history, BEXIMCO PHARMA manufactured medicines under licenses from Bayer AG of Germany and Upjohn of the United States. This licensing-based phase gave the company access to established pharmaceutical products and manufacturing know-how. Its later development centered on creating, manufacturing, and marketing its own branded generic medicines rather than remaining solely a license manufacturer. The company subsequently built a portfolio covering several major therapeutic categories. Reference material identifies products for AIDS, cancer, asthma, hypertension, and diabetes among its areas of activity. BEXIMCO PHARMA serves the Bangladeshi market and has pursued international distribution through exports. In 2007, it exported medicines to the Philippines, making that country one of the ASEAN markets importing its products. The company is also identified as the first pharmaceutical company from Bangladesh to sell its products in the United States, marking an important step in the internationalization of the Bangladeshi pharmaceutical industry. Its manufacturing base is located on an approximately 20-acre site in Dhaka. The site includes several purpose-built plants, a newer oral solid dosage plant, a research laboratory, and warehouses. The production complex was developed with plant and machinery supplied or installed by international partners from countries including Germany, Switzerland, Sweden, Italy, and the United Kingdom. The combination of manufacturing, research, and storage facilities supports the company's branded generic portfolio and export operations. The COVID-19 pandemic became a major recent turning point in the company's public profile. In May 2020, BEXIMCO PHARMA introduced a generic version of remdesivir for COVID-19 treatment. The company characterized this as the world's first generic remdesivir. It later became the first company to obtain production and marketing authorization for molnupiravir in Bangladesh together with Eskayef Pharmaceuticals. BEXIMCO PHARMA marketed its branded generic molnupiravir as Emorivir. Taken together, the available history presents BEXIMCO PHARMA as a Bangladesh-based branded-generics manufacturer that progressed from licensed production to proprietary branded generic medicines, expanded through exports, entered the United States market, and used its manufacturing platform to participate in pandemic-related antiviral supply. The supplied reference material does not establish a complete list of current or former executives, detailed ownership information, financial results, or a verified current corporate website URL.
- 2020
Generic remdesivir introduced
[1]In May 2020, the company introduced a generic version of remdesivir for COVID-19 treatment.
- 2007
Export expansion to the Philippines
[1]BEXIMCO PHARMA exported medicines to the Philippines, one of its ASEAN destination markets.
- 1980
Operations begin
[1]The company began pharmaceutical operations, initially manufacturing products under licenses from Bayer AG and Upjohn.
- 1976
Company founded
[1]Beximco Pharmaceuticals was founded in Bangladesh as part of the wider BEXIMCO business group.
First Bangladeshi pharmaceutical company to sell in the United States
[1]The company became the first pharmaceutical company from Bangladesh to sell its products in the United States.
Molnupiravir authorization and Emorivir launch
[1]Together with Eskayef Pharmaceuticals, BEXIMCO PHARMA obtained authorization to produce and market molnupiravir in Bangladesh and marketed its version as Emorivir.
Products and positioning
A Bangladesh-based multinational pharmaceutical manufacturer focused on branded generic medicines, domestic healthcare supply, exports, and expansion into international regulated markets.
Pharmaceuticals
Branded generic medicines
BEXIMCO PHARMA's core business is the manufacture and marketing of branded generic medicines. The portfolio spans multiple therapeutic areas, including infectious diseases, oncology, respiratory conditions, hypertension, and diabetes. The company serves Bangladesh and export markets.
Antiviral medicine · 2020
Generic remdesivir
A generic version of remdesivir introduced by BEXIMCO PHARMA in May 2020 for COVID-19 treatment. The company presented it as the world's first generic remdesivir.
Antiviral medicine
Emorivir
BEXIMCO PHARMA's branded generic version of molnupiravir, marketed in Bangladesh after the company and Eskayef Pharmaceuticals obtained production and marketing authorization.
Brand decisions
2020
Rapid entry into generic remdesivir productionProduct launchBackground
The COVID-19 pandemic created urgent demand for antiviral treatments and increased attention to the availability of generic medicines.
Action taken
BEXIMCO PHARMA introduced a generic version of remdesivir in May 2020.
Aftermath
The move positioned the company as an early Bangladesh-based participant in pandemic antiviral manufacturing and attracted international attention.
- Authorization and commercialization of molnupiravirProduct launch
Background
BEXIMCO PHARMA pursued authorization for molnupiravir as an oral COVID-19 treatment in Bangladesh.
Action taken
Together with Eskayef Pharmaceuticals, the company obtained production and marketing authorization and marketed its branded generic version as Emorivir.
Aftermath
The decision expanded the company's pandemic-related antiviral offering beyond remdesivir.
Recent events
- Unconfirmed
Reported
Beximco launches Bexovid in Bangladesh[2]
Beximco Pharmaceuticals launched Bexovid, a generic version of Pfizer's Covid-19 treatment Paxlovid, initially in Bangladesh.
Reported
Beximco completes acquisition of majority stake in Sanofi Bangladesh[3]
Beximco Pharmaceuticals completed its acquisition of a majority stake in Sanofi Bangladesh.
- Unconfirmed
Beximco Pharma launches Emorivir generic molnupiravir[4]
Beximco Pharmaceuticals announced the launch of Emorivir, its branded generic version of molnupiravir, following emergency use authorisation by Bangladesh's Directorate General of Drug Administration.
Beximco Pharma signs agreement to acquire majority stake in Sanofi Bangladesh[5]
Beximco Pharmaceuticals signed a final agreement to acquire a 54.6% stake in Sanofi Bangladesh for over Tk 400 crore. The share handover had started; completion was to be confirmed in a further announcement.
Sources5 sources
Cite this profile: Cite the canonical profile. /brand-wiki/beximco-pharma · Editorial policy · How profiles are compiled